Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout

Table 4 Serum urate target and measures of gout activity

	At SU target (<0.36 mmol/L)	Above SU target (≥0.36 mmol/L)	p
	n = 89	n = 184	p
Flare frequency, mean (SD)	1.2 (2.3)	3.2 (11.4)	0.03
Presence of tophi, n (%)	9 (10%)	34 (18.5%)	0.08
HAQ-II, mean (SD)	0.46 (0.52)	0.51 (0.63)	0.46
Days off work due to gout, mean (SD)	1.2 (5.6)	0.9 (3.3)	0.52

ISSN: 1471-2474